Gregory J. Riely
Lung cancer doctor who led PHAROS, the trial that brought the encorafenib and binimetinib pair to BRAF V600E-mutant lung cancer.
Overview
Gregory Riely is a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center. He was first author of the 2023 Journal of Clinical Oncology report of PHAROS, the phase 2 trial of encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer that supported the combination's approval, and has long worked on KRAS-mutant lung cancer and the clinical use of tumour genotyping.
Similar pages
not linked directly; found by shared links- PersonPaul K. Paik
Shares Lung cancer (all types), Memorial Sloan Kettering Cancer Center, Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
- PersonAlice T. Shaw
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
- PersonKeunchil Park
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
- PersonMatthew D. Hellmann
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, trialist.
- PersonRobert C. Doebele
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.
- PersonPaul B. Chapman
Shares Memorial Sloan Kettering Cancer Center and the tags targeted-therapy, trialist.
- PersonRona Yaeger
Shares Memorial Sloan Kettering Cancer Center and the tags targeted-therapy, trialist.
- PersonFerdinandos Skoulidis
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.